SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting highly positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, showcasing strong efficacy and potential disease-modifying effects. This, combined with a robust financial position and an eagerly awaited Investor Day, is fueling community discussion around significant undervaluation, a potential short squeeze, and best-in-class potential for its nanobody platform.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for Bysanti, a new treatment for bipolar I disorder and schizophrenia, which was granted New Chemical Entity (NCE) status with patent protection extending to 2044. The community is actively discussing this as a major re-rating catalyst, anticipating significant institutional buying, and speculating on the drug's blockbuster potential alongside future pipeline developments.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ trends as the market grapples with the fallout from the Supreme Court's tariff ruling and the subsequent 15% global tariffs, fueling community debate on economic uncertainty and the tech index's consistent resilience ahead of Nvidia's pivotal earnings.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

The recent acquisition of Astria Therapeutics, integrating the late-stage HAE drug navenibart, is driving BioCryst's conversation, especially with new data presentations for navenibart and Orladeyo expected at a medical conference and upcoming earnings. The community is actively discussing the potential of these pipeline advancements against persistent concerns about the stock's valuation and significant short interest.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending with strong community enthusiasm surrounding its anticipated BLA resubmission for deramiocel by the end of February, driving speculation for accelerated FDA approval and potential buyout interest, all while institutional ownership continues to increase.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as the community hotly debates the immense potential of its advanced GaN and SiC power platforms for next-gen AI data centers, particularly its role in NVIDIA's AI ecosystem. Despite the recognized breakthrough technology addressing critical efficiency needs, investors are expressing significant concern over the current absence of definitive, revenue-generating contracts, especially ahead of its upcoming earnings report.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending due to a dual financing announcement, including a non-dilutive royalty deal for its prostate cancer candidate and a concurrent public offering, which has sparked intense community debate over dilution and management's long-term commercialization strategy. Bulls view the capital raise as crucial validation and runway for its promising oncology pipeline, while bears express strong concerns about shareholder value and the impact on a potential "go it alone" approach.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending following its Lightwave Award win for advanced AI connectivity, driving significant community speculation about impending commercialization updates at the upcoming OFC Conference. The market is actively discussing institutional accumulation and the company's validated strategic importance in AI data center optical interconnects, especially after the Marvell-Celestial AI acquisition.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending following a volatile reaction to its Q2 earnings, where an initial sell-off due to a revenue miss and one-time charges quickly reversed as the community focused on its robust AI/GPU growth guidance. Investors are now discussing the strategic pivot towards a 4.5 GW AI infrastructure powerhouse, backed by significant GPU financing, outweighing short-term financial noise.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending intensely following ANKTIVA's conditional marketing authorization across 33 European countries and accelerated approval in Saudi Arabia for lung cancer, sparking community excitement over immediate global revenue growth and an anticipated short squeeze, as many view Dr. Patrick Soon-Shiong's immunotherapy platform as an "unstoppable" force in cancer treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanguard Group Inc. Trims Stake in Sterling Infrastructure, Inc. $STRL

Vanguard Group Inc. lowered its position in Sterling Infrastructure, Inc. (NASDAQ:STRL - Free Report) by 5.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with...

Sterling Infrastructure (NASDAQ:STRL) Trading 6.2% Higher - What's Next?

Sterling Infrastructure (NASDAQ:STRL) Shares Up 6.2% - Still a Buy...

Sterling Infrastructure (STRL) Increases Despite Market Slip: Here's What You Need to Know

Sterling Infrastructure (STRL) closed at $415.13 in the latest trading session, marking a +1.1% move from the prior day.

Here's What You Must Know Ahead of Primoris Services' Q4 Earnings

PRIM gears up for Q4 earnings as weather, pipeline weakness and lower storm work weigh on margins despite strong solar and utility momentum.



Should Investors Hold or Fold Sterling Stock Ahead of Q4 Earnings?

STRL's fourth-quarter results are likely to reflect strength in high-margin infrastructure work, geographic expansion and disciplined project execution.

Sterling Infrastructure (STRL) Earnings Expected to Grow: Should You Buy?

Sterling Infrastructure (STRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shell Asset Management Co. Sells 2,387 Shares of Sterling Infrastructure, Inc. $STRL

Shell Asset Management Co. decreased its stake in shares of Sterling Infrastructure, Inc. (NASDAQ:STRL - Free Report) by 62.6% during the 3rd quarter, according to its most recent 13F filing with the...

Sterling Infrastructure (STRL) to Release Earnings on Wednesday

Sterling Infrastructure (NASDAQ:STRL) will be releasing its Q4 2025 earnings after the market closes on Wednesday, February 25. (View Earnings Report at...

Quanta is Set to Report Q4 Earnings: Here's What Investors Must Know

PWR gears up for Q4 results with record $39.2B backlog and strong Electric demand, but margin and project timing risks might cloud the outlook.

Sterling's Transportation Margins Rebound: A Structural Shift?

STRL's Transportation margins rise as it pivots from low-bid highway jobs to higher-margin projects, marking a strategic reset with stronger backlog visibility.

Sterling Infrastructure, Inc. engages in the provision of construction solutions. It operates through the following segments: Transportation Solutions, E-Infrastructure Solutions, and Building Solutions. The Transportation Solutions segment includes infrastructure and rehabilitation projects for highways, roads, bridges, airports, ports, light rail, water, wastewater, and storm drainage systems. The E-Infrastructure Solutions projects develop advanced, large-scale site development systems and services for data centers, e-commerce distribution centers, warehousing, transportation, energy, and more. The Building Solutions segment projects include residential and commercial concrete foundations for single-family and multi-family homes, parking structures, elevated slabs, and other concrete work. The company was founded in 1955 and is headquartered in The Woodlands, TX.

STRL
Sterling Construction Company, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest STRL News

STRLSterling Construction Company, Inc.